TW202104255A - 用於治療及診斷之新穎分子 - Google Patents

用於治療及診斷之新穎分子 Download PDF

Info

Publication number
TW202104255A
TW202104255A TW109113222A TW109113222A TW202104255A TW 202104255 A TW202104255 A TW 202104255A TW 109113222 A TW109113222 A TW 109113222A TW 109113222 A TW109113222 A TW 109113222A TW 202104255 A TW202104255 A TW 202104255A
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
acid sequence
sequence
variable region
Prior art date
Application number
TW109113222A
Other languages
English (en)
Chinese (zh)
Inventor
艾爾皮達 齊卡
約翰 華納
羅曼 克里斯帝安 奧利耶爾
Original Assignee
瑞士商Ａｃ免疫公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商Ａｃ免疫公司 filed Critical 瑞士商Ａｃ免疫公司
Publication of TW202104255A publication Critical patent/TW202104255A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW109113222A 2019-04-18 2020-04-20 用於治療及診斷之新穎分子 TW202104255A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP19170207 2019-04-18
EP19170207.5 2019-04-18
EP19207105 2019-11-05
EP19207105.8 2019-11-05
EP20165055.3 2020-03-23
EP20165055 2020-03-23

Publications (1)

Publication Number Publication Date
TW202104255A true TW202104255A (zh) 2021-02-01

Family

ID=70285703

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109113222A TW202104255A (zh) 2019-04-18 2020-04-20 用於治療及診斷之新穎分子

Country Status (10)

Country Link
US (1) US12534519B2 (https=)
EP (1) EP3956027A1 (https=)
JP (1) JP7689373B2 (https=)
KR (1) KR20210154179A (https=)
CN (2) CN121873233A (https=)
AU (1) AU2020258025A1 (https=)
CA (1) CA3133909A1 (https=)
MX (1) MX2021012608A (https=)
TW (1) TW202104255A (https=)
WO (1) WO2020212593A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113912712A (zh) * 2021-12-15 2022-01-11 北京凯祥弘康生物科技有限公司 抗α-突触核蛋白的单克隆抗体的制备及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
JPWO2022265091A1 (https=) * 2021-06-18 2022-12-22
CN113912714B (zh) * 2021-12-15 2022-02-22 北京凯祥弘康生物科技有限公司 特异性结合α-突触核蛋白的抗体及其应用
KR20240176098A (ko) * 2023-06-14 2024-12-24 경상국립대학교산학협력단 알파 시누클레인 에피토프를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물
WO2025093720A1 (en) 2023-11-02 2025-05-08 Betasense Gmbh Methods for determining misfolded alpha-synuclein in a sample
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
WO2025158162A1 (en) * 2024-01-25 2025-07-31 Imperial College Innovations Limited Alpha-synuclein antibody
CN120064410A (zh) * 2025-04-28 2025-05-30 协和生物制药（天津）有限公司 一种用于α-突触核蛋白检测的电化学生物传感器

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US20050147989A1 (en) * 2003-10-02 2005-07-07 Uwe Bertsch Screening assay for aggregations
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
JP6325463B2 (ja) 2012-03-16 2018-05-16 コヴァジェン アクチェン ゲゼルシャフト 抗腫瘍活性を有する新規結合分子
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10160800B2 (en) 2016-06-02 2018-12-25 Medimmune Limited Antibodies to α-synuclein and uses thereof
BR112018014281A2 (pt) * 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
EP3555127B1 (en) * 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, uses and methods
US11155608B2 (en) * 2017-08-23 2021-10-26 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113912712A (zh) * 2021-12-15 2022-01-11 北京凯祥弘康生物科技有限公司 抗α-突触核蛋白的单克隆抗体的制备及其应用
CN113912712B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 抗α-突触核蛋白的单克隆抗体的制备及其应用

Also Published As

Publication number Publication date
JP7689373B2 (ja) 2025-06-06
EP3956027A1 (en) 2022-02-23
CN114206444A (zh) 2022-03-18
CN114206444B (zh) 2026-01-06
CA3133909A1 (en) 2020-10-22
CN121873233A (zh) 2026-04-17
AU2020258025A1 (en) 2021-11-25
JP2022529344A (ja) 2022-06-21
KR20210154179A (ko) 2021-12-20
US20220298231A1 (en) 2022-09-22
US12534519B2 (en) 2026-01-27
MX2021012608A (es) 2021-11-12
WO2020212593A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
JP7689373B2 (ja) 治療及び診断のための新規分子
JP7330977B2 (ja) Ｗｎｔサロゲート分子及びその使用
JP7101927B2 (ja) 抗トランスサイレチン抗体
JP7317016B2 (ja) 抗ｌｒｐ５／６抗体及び使用方法
JP2023504699A (ja) 治療および診断のための新規な分子
JP2024001292A (ja) 多特異性Ｗｎｔ代替分子及びその使用
TW201900682A (zh) 抗ｐｈｆ－ｔａｕ抗體及其用途
JP2024009870A (ja) 抗ｐｈｆ－タウ抗体及びその使用
CN115697393A (zh) 抗PHF-tau抗体及其用途
JP2021508498A (ja) 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
US20240150451A1 (en) Anti-tau antibodies and uses thereof
US20250320283A1 (en) Antibodies Binding to Alpha-Synuclein for Therapy and Diagnosis
HK40071061A (en) Novel molecules for therapy and diagnosis
HK40074240A (en) Novel molecules for therapy and diagnosis
CN117083298A (zh) 针对成对螺旋细丝tau的人源化抗体及其用途